We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.85 | 1.80 | 1.90 | 1.85 | 1.85 | 1.85 | 572,013 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 4.47M | -40.44M | -0.0522 | -0.35 | 14.35M |
Date | Subject | Author | Discuss |
---|---|---|---|
28/9/2023 09:03 | Yes but they get the tenners from PI's, so they are happy to do so. | encarter | |
28/9/2023 08:59 | Here's another way to look at it... why would you hold it now? Given the track record, I'd much rather buy it at 20p in 2026 when they are making NET profits and miss out on this cycle of raise and repeat. They are paying tenners to make fivers at the moment. The maths doesn't work for me anymore, I'm out (at a ridiculous loss) | reviewwworld | |
28/9/2023 08:57 | Sales are up, price per unit disappointing, more shares issued - jam tomorrow, but it keeps getting watered down in stock issues. | weatherman | |
28/9/2023 08:55 | Question is whether to buy in the retail offer at 8p or whether to wait and see if the market takes the share price sub 8p. | husbod | |
28/9/2023 08:53 | About 700 million shares in issue plus millions of warrants No way in million years this company should be worth 60 plus millionI see the share price tanking well below all time lowGet out whilst you can | hamidahamida | |
28/9/2023 08:51 | How many did you buy this week patt ? | arab3 | |
28/9/2023 08:46 | When this placing will be done? | qipincha | |
28/9/2023 08:45 | Stepping back from the hysteria, it is rather impressive to see this level of growth and the likelihood is that they will be hitting the upper end of the 100,000 to 130,000 prescriptions target for the year. With the Canada decision soon, the Korean PK study and the possibilities in China, too, there is a lot to be excited about for the company and the shareholders. US selling price trajectory is following a predictable path if you are experienced in market access (I work in a pharma market access function). AOP are no fools. | photon | |
28/9/2023 08:37 | Funds for US listing? | little minx | |
28/9/2023 08:35 | Imo No chance they are going to meet forecasts This is going well below the issue price Boiler room boys hv been stung | hamidahamida | |
28/9/2023 08:31 | Why would you raise money after telling the market only few weeks ago they have enough money to reach break even. Pretty obvious it's probably becoming evident they are not going to meet forecasts hence the reason for this deeply discounted confetti party. | hamidahamida | |
28/9/2023 08:31 | Early indications suggest Accrufer's(R) growth trajectory will continue to rise in Q3 2023, exceeding 28,400 prescriptions, representing an 80% sequential increase vs Q2. The prescriptions in Q3 2023 are on track to exceed the total for the entire first six months of the year. Excellent initial results following the commercial expansion put Shield on track to reach a major corporate milestone for 2023, with line of sight to total Accrufer(R) prescriptions of 100,000 to 130,000. Since the completion of the sales force expansion in May, Accrufer(R) has grown an average of 26% month over month through to the end of August. | qipincha | |
28/9/2023 08:27 | You were saying? | little minx | |
28/9/2023 08:24 | Look on the Brightside folks The placing is at a 0% discount to the share price today. What great business from the board. | lako42 | |
28/9/2023 08:21 | If you cannot see why LTH's are miffed with this latest raise, especially after the trading activity yesterday...then I simply do not believe you. Sure, people could and some did, make money trading between the last raise and this one. And that is probably the only way to make money in this type of outfit. But it is essentially playing greater fool theory, because this is not the first time that irregular share price activity has taken place, followed by the predictable. Smaller and smaller potential returns for shareholders, while the BOD feast. Actual update OK, but even if they do eventually stop relying on placings to keep as a going concern, no doubt the BOD will elevate their remuneration even higher than it already is. Meaning actual long term investors, even if they had participated in all the raises, are going to make only a small profit, at best. No way is this going to be a 10 bagger, because they are going to keep rewarding themselves ever greater chunks of the company. Anyway, it is what it is on AIM. GLA. | lovewinshatelosses | |
28/9/2023 08:20 | Says it all. | little minx | |
28/9/2023 08:17 | Ok, back to August time, and hold | qipincha |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions